MOLECULAR BIOLOGY
Molecular study of an environmental carcinogen
E. Bresnick PhD (Beverly MA)
Tumor suppressor genes & cell cycle
D. Haber MD Mass General
Telomerase-diagnostic application
H. Tahara MD Univ Hiroshima
Regulation of p53 stability
Z. Ronai PhD St. Savin NY
Stromal-epithelial interactions
LWK Chung PhD Univ Virginia
Genetic predisposition & therapy
G. Thomas MD St. Antoine Paris

COFACTORIAL INFLUENCES
Environmental & genotoxic exposures
M. Varrillo MD IRC Lyon
Viral effects
G. de The MD Pasteur Paris
Endocrine regulation of differentiation
M. Gottardis MD Legrand
Nutrition-cancer relationship
H. Adami MD Karolinska Inst
Helicobacter pylori & stomach cancer
D. Patil MD Careggi Florence
AIDS-assoc. tumors
H. Itochim MD Tokyo JPN

MULTIFACTORIAL DIAGNOSIS
Gene analysis on electronic microchips
M. Nerenberg PhD Noyen
Genetic susceptibility & DNA adducts
H. Barcza PhD DKZ Heidelberg
DNA methylation-chromosome aberr.
J. M. Trent PhD NCHGR Bethesda
Microsatellite analysis for early detection
I. Mao MD UTX MDA
Prostate-precursor lesions & prognosis
D. Q. Bostwick MD Mayo Clinic
Predictive assessment of multidrug resistance
P. Sonneveld MD Rotterdam

MOLECULAR THERAPY
Gene therapy progress
W. H. Friedman MD Curie Paris
Advances in gene therapy vectors
B. Huber MD Genentech Mountain View
Telomerase inhibition
A. Harsch MD Isern
Pancreas-farnesyl transferase inhibition
J. L. Blumberg MD
Novel differentiation agents
S. W. Zeevman MD Mt Sinai NY

RISK ASSESSMENT
p53 in normal epithelium adjacent to h/n ca.
T. S. A. J. Bos PhD MDA Heidelberg
Telomerase in normal mucosa adjacent to ca.
D. K. Kim MD Genentech
k-ras mutations in normal tissue: lung cancer
F. Minamoto MD Univ Kanazawa
DNA adducts in normal tissue adjacent to ca.
D. L. U. West MD
DNA in normal tissue adjacent to colon ca.
J. B. Bauria MD NCI Bethesda
LOH in normal tissue adjacent to breast cancer
K. D. Stepney MD San Francisco

PREDICTIVE MARKERS
Genetics of glioma progression
P. Kleihues MD IRC Lyon
Cell cycle inhibitor protein p27
J. M. Slingerland MD San Antonio
Prognostic oncogene expression
E. U. Bernt MD Rotterdam
Tumor angiogenesis & inhibition
W. J. Hrushesky MD Albany Med
Biotech. in cancer epidemiology studies
R. Hayes MD NCI Bethesda

NOVEL IMMUNOTHERAPY
Novel human intra-tumoral immunother.
T. E. Taniguchi MD Gifu Japan
Cytotoxic T lymphocytes & IL-2
N. Restifo MD NCI Bethesda
Dendritic cells in immunotherapy
H. Bollen MD Cologne
Breast-target-recognizing TIL
F. Maringola MD NCI Bethesda
Clinical use of antisense strategies
A. M. Gevitz MD Univ Pennsylvania
Xenotherapy
M. Souloumi MD Univ. Bern
Notice to Members of the American Association for Cancer Research (AACR)

Officers for 1998–1999
President: Webster K. Cavenee, Ludwig Institute for Cancer Research, La Jolla, CA 92093-0660
President-Elect: Daniel D. Von Hoff, Institute for Drug Development, San Antonio, TX 78245
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 826, Philadelphia, PA 19106-3483

Annual Dues
The annual dues of active members of the AACR are $175. $50 of which may be applied to a subscription to Clinical Cancer Research. Corresponding members of the Association will be charged an appropriate fee to offset periodicals postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Phone: (215) 440-9300; FAX: (215) 440-9313.

Submission of Manuscripts
Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients. All submissions undergo peer review. Papers should be sent directly to an appropriate Senior Editor or to the Editor-in-Chief for review. See “Instructions for Authors” (page ii of this issue) for complete mailing addresses of the Editor-in-Chief, Deputy Editor, and Senior Editors.

Back Issues and Single Copy Sales of the Journal
Copies of back stock of the journal may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Phone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588]. As long as supplies permit, single copies will be sold by this company at $25.00/copy. Orders outside the U.S. add $3/copy to offset postage costs.

Advertisements
Advertisement insertion orders and copy must be received one month prior to the date of issue in which the advertisement is to be published. The journal is mailed on approximately the 1st day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Ave., Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Copyright and Permissions
Authors who wish to publish in Clinical Cancer Research must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AACR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors before corresponding with the AACR.

Those who wish to photocopy articles should contact the AACR Publications Department [Phone: (215) 440-9300; FAX: (215) 440-9354].

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Clinical Cancer Research is abstracted and/or indexed in Cancer Lit, Chemical Abstracts, Current Contents/Clinical Medicine, and Index Medicus/MEDLINE.

Clinical Cancer Research (ISSN 1078-0432) is published monthly by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for $50 annually for members and $120 for individual nonmembers. Clinical Cancer Research is only available to institutions as a combined subscription with Cancer Research. The combined 1998 institutional subscription price of $795 includes $210 for a subscription to Clinical Cancer Research. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copyright 1998 by the American Association for Cancer Research, Inc. Printed on acid-free paper in the U.S.A.
**ANTI-CANCER PROTEINS AND DRUGS: STRUCTURE, FUNCTION AND DESIGN**

**A New York Academy of Sciences Conference**

**November 6–9, 1998 at The Rockefeller University**

Researchers working on tumor suppressor genes and on anti-cancer drugs, including Robert Weinberg and Frank McCormick, will discuss the therapeutic potential of these discoveries and will focus on cutting-edge anti-cancer protein/drug research issues. This conference is designed to promote a comprehensive understanding and cooperation between industrial and academic researchers, in order to facilitate the design and creation of more effective anti-cancer molecules for the treatment of cancers.

**Sessions:**
- Nuclear Proteins
- Cytoplasmic Proteins
- Extracellular Proteins
- Anti-Cancer Drugs
- DNA or Peptide Delivery/Targeting

**Call for Abstracts:** July 31, 1998 submission deadline.

---

**Rapid Access to Intervention Development**

**“RAID”**

The **National Cancer Institute** announces a new initiative: Rapid Access to Intervention Development (RAID). RAID will make available to academic investigators, on a competitive basis, the preclinical development contract resources of NCI’s Developmental Therapeutics Program. The goal of RAID is the rapid movement of novel molecules and concepts from the laboratory to the clinic for proof-of-principle clinical trials. RAID will assist investigators who submit successful applications by providing any (or all) of the preclinical development steps that may be obstacles to clinical translation. These may include, for example, production, bulk supply, GMP manufacturing, formulation, and toxicology. Suitable agents for RAID will include small molecules, biologics, or vaccines. The first group of proposals will be received by August 1, 1998. Thereafter, there will be two receipt dates per year, February 1, and August 1, with all materials submitted directly to the office listed below. For information on process and procedure, visit the web site. http://epnws1.ncifcrf.gov:2345/dis3d/raidfin.html. Inquiries are encouraged, and the opportunity to clarify issues or questions is welcome. Please contact:

**RAID, Office of Associate Director**
Developmental Therapeutics Program, NCI
Executive Plaza North, Suite 843
6130 Executive Blvd., Rockville, MD 20852
Tel: 301.496.8720; Fax: 301.402.0831
Email: sausville@dtpax2.ncifcrf.gov

---

**A New Resource Kit from the National Cancer Institute**

To order this and other materials, call the
Cancer Information Service, a program of the
National Cancer Institute at

**1-800-4-CANCER**

(1-800-422-6237)

People with TTY equipment, dial **1-800-332-8615**
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Cellular Targets of Viral Carcinogenesis

September 24-28, 1998
Marriott’s Laguna Cliffs Resort
Dana Point, California

CONFERENCE CHAIRPERSONS
Thea D. Tlsty / San Francisco, CA
Eileen P. White / Piscataway, NJ
Don Ganem / San Francisco, CA
Carol Prives / New York, NY

TENTATIVE SCIENTIFIC PROGRAM

Cell Cycle
Jean Y. J. Wang / La Jolla, CA
William Kaelin / Boston, MA
Karen H. Vousden / Frederick, MD
Thomas E. Shenk / Princeton, NJ

Signal Transduction
Daniel C. DiMaio / New Haven, CT
Elliott Kieff / Boston, MA

Apoptosis
Eileen P. White / Piscataway, NJ
Anne E. Griepp / Madison, WI
Philip E. Branton / Montreal, Canada

Genomic Instability
Carol Prives / New York, NY
Thea D. Tlsty / San Francisco, CA
Michael R. Botchan / Berkeley, CA

Evasion of Host Cell Defenses
Grant McFadden / London, Canada
Marshall S. Horwitz / Bronx, NY
Robert H. Silverman / Cleveland, OH

Cell Proliferation
Karl Munger / Boston, MA
Elizabeth Moran / Philadelphia, PA
Don Ganem / San Francisco, CA

Animal Models
Francis V. Chisari / La Jolla, CA
Lisa M. Coussens / San Francisco, CA
Douglas Hanahan / San Francisco, CA

Therapeutic Opportunities
Pramod K. Srivastava / Farmington, CT
David H. Kirn / Richmond, CA

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation. Selected proffered papers will also be scheduled for oral presentations.

Application deadline: July 13, 1998

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
e-mail: aacr@aacr.org
AACR Website: http://www.aacr.org